US · ENSG · MEDICAL - CARE FACILITIES
The Ensign Group, Inc. (ENSG) intrinsic value and stock valuation
$176.32as of 2026-11-21 · Mkt cap 10.66B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
The Ensign Group, Inc. DCF and intrinsic value
InvestorsCraft values ENSG with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from ENSG’s statements →
The Ensign Group, Inc. Graham Number
Graham Number: $72.57d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Solventum Corporation (SOLV) $84.50
- Exelixis, Inc. (EXEL) $64.63
- Elanco Animal Health Incorporated (ELAN) $25.74
- Revvity, Inc. (RVTY) $145.22
- Align Technology, Inc. (ALGN) $155.17
- DaVita Inc. (DVA) $161.03
- BioMarin Pharmaceutical Inc. (BMRN) $60.41
- Encompass Health Corporation (EHC) $133.65
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $5.06B | $4.26B | $3.73B | $3.03B | $2.63B |
| Operating income | $425.3M | $358.3M | $255.4M | $296.8M | $260.5M |
| Net income | $344M | $298M | $209.4M | $224.7M | $194.7M |
| EPSd | $5.84M | $5.12M | $3.65M | $3.95M | $3.42M |
| Operating cash flow | $564.3M | $347.2M | $376.7M | $272.5M | $275.7M |
| Capital expenditure | -$-193.56M | -$-158.24M | -$-106.18M | -$-87.55M | -$-69.55M |
| Free cash flow | $370.7M | $189M | $270.5M | $185M | $206.1M |
| Total assets | $5.46B | $4.67B | $4.18B | $3.45B | $2.85B |
| Total debt | $4.16B | $1.97B | $1.87B | $1.57B | $1.27B |
| Net debt | $3.65B | $1.51B | $1.36B | $1.26B | $1B |
| Total equity | $2.23B | $1.84B | $1.5B | $1.25B | $1.02B |
| Cash and short-term investments | $572.4M | $526.9M | $526.9M | $331.7M | $276M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $5.06B | $4.26B | $3.73B | $3.03B | $2.63B |
| Cost of revenue | $4.26B | $3.59B | $3.14B | $2.51B | $2.16B |
| Gross profit | $799.5M | $667.6M | $590.8M | $518M | $468.2M |
| Research and development expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Selling, general and administrative expenses | $269.8M | $225.1M | $263M | $158.8M | $151.8M |
| Other expenses | $104.3M | $84.1M | $72.4M | $62.4M | $56M |
| Operating expenses | $374.2M | $309.3M | $335.4M | $221.2M | $207.8M |
| Cost and expenses | $4.63B | $3.9B | $3.47B | $2.73B | $2.37B |
| Interest income | $24.5M | $28.8M | $19.2M | $5.04M | $4.39M |
| Interest expense | $7.99M | $8.29M | $8.09M | $8.93M | $6.85M |
| Depreciation and amortization | $104.3M | $84.1M | $72.4M | $62.4M | $56M |
| Ebitda | $567.9M | $478.5M | $353.2M | $360.4M | $320.8M |
| Operating income | $425.3M | $358.3M | $255.4M | $296.8M | $260.5M |
| Total other income/expenses, net | $30.3M | $27.8M | $17.4M | -$-7.74M | -$-2.46M |
| Income before tax | $455.6M | $386.1M | $272.8M | $289.1M | $258M |
| Income tax expense | $111.4M | $87.6M | $62.9M | $64.4M | $60.3M |
| Net income | $344M | $298M | $209.4M | $224.7M | $194.7M |
| Weighted average shares outstanding | $57.3M | $56.7M | $55.7M | $54.9M | $54.5M |
| Weighted average diluted shares outstanding | $58.9M | $58.2M | $57.3M | $56.9M | $56.9M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $572.4M | $526.9M | $526.9M | $331.7M | $276M |
| Net receivables | $637M | $569.9M | $485M | $408.4M | $328.7M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $1.27B | $1.16B | $1.05B | $781.1M | $639.7M |
| Property, plant and equipment, net | $3.79B | $3.15B | $2.85B | $2.44B | $2.03B |
| Goodwill and intangible assets | $104.4M | $105.3M | $83.4M | $83.3M | $66.9M |
| Long-term investments | $166.8M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $4.19B | $3.51B | $3.13B | $2.67B | $2.21B |
| Total assets | $5.46B | $4.67B | $4.18B | $3.45B | $2.85B |
| Accounts payable | $97.3M | $99M | $92.8M | $77.1M | $58.1M |
| Short-term debt | $119M | $97.6M | $86.5M | $69.7M | $55.9M |
| Deferred revenue | $105.6M | $18.8M | $10.8M | $9.7M | $9.34M |
| Total current liabilities | $894.4M | $743.4M | $734.8M | $582.1M | $523.1M |
| Long-term debt | $4.04B | $1.88B | $1.78B | $1.5B | $1.21B |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $2.33B | $2.09B | $1.95B | $1.62B | $1.31B |
| Capital lease obligations | $2.06B | $1.83B | $1.72B | $1.42B | $1.11B |
| Total liabilities | $3.23B | $2.83B | $2.68B | $2.2B | $1.83B |
| Common stock | $60K | $60K | $60K | $60K | $60K |
| Retained earnings | $1.76B | $1.43B | $1.14B | $946.3M | $734M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $2.23B | $1.84B | $1.5B | $1.25B | $1.02B |
| Total investments | $235.4M | $62.3M | $17.2M | $15.4M | $13.8M |
| Total debt | $4.16B | $1.97B | $1.87B | $1.57B | $1.27B |
| Net debt | $3.65B | $1.51B | $1.36B | $1.26B | $1B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $344.3M | $298.5M | $209.9M | $224.7M | $197.7M |
| Depreciation and amortization | $104.3M | $84.1M | $72.4M | $62.4M | $56M |
| Stock-based compensation | $48.3M | $36.2M | $30.8M | $22.7M | $18.7M |
| Change in working capital | $77.9M | -$-75.16M | $37.9M | -$-36.94M | $30K |
| Accounts receivable | -$-70.43M | -$-84.4M | -$-79.82M | -$-82.43M | -$-30.77M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-2.92M | $2.83M | $15.9M | $17.9M | $7.12M |
| Net cash provided by operating activities | $564.3M | $347.2M | $376.7M | $272.5M | $275.7M |
| Investments in property, plant and equipment | -$-193.56M | -$-158.24M | -$-106.18M | -$-87.55M | -$-69.55M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$-16.4M | -$-7.98M |
| Net cash used for investing activities | -$-513.18M | -$-390.05M | -$-182.7M | -$-186.18M | -$-173.91M |
| Common stock issued | $29M | $0.00 | $0.00 | $6.69M | $0.00 |
| Common stock repurchased | -$-21.43M | -$-1.21M | -$-1.93M | -$-31.58M | -$-11.83M |
| Dividends paid | -$-14.41M | -$-13.67M | -$-12.89M | -$-12.17M | -$-11.55M |
| Net cash used for financing activities | -$-11.81M | -$-2.16M | -$-610K | -$-32.26M | -$-76.14M |
| Net change in cash | $39.3M | -$-45.03M | $193.4M | $54.1M | $25.6M |
| Cash at end of period | $503.9M | $464.6M | $509.6M | $316.3M | $262.2M |
| Operating cash flow | $564.3M | $347.2M | $376.7M | $272.5M | $275.7M |
| Capital expenditure | -$-193.56M | -$-158.24M | -$-106.18M | -$-87.55M | -$-69.55M |
| Free cash flow | $370.7M | $189M | $270.5M | $185M | $206.1M |
Line items
Line items
Line items
About The Ensign Group, Inc.
The Ensign Group, Inc. operates as a healthcare provider, primarily concentrating on post-acute care services, alongside other supporting business ventures. The company's activities are organized into two main divisions: Skilled Services and Real Estate. Within its Skilled Services segment, Ensign provides extensive short-term and long-term nursing care tailored for patients recovering from extended illnesses, managing chronic health conditions, or requiring elder care. This division also encompasses a variety of rehabilitative therapies, such as physical, occupational, and speech therapy, among other specialized healthcare provisions. Beyond direct medical care, the company furnishes essential amenities like lodging, customized dietary programs, and opportunities for social engagement, recreation, and entertainment. Ensign additionally manages senior living facilities and delivers convenient mobile diagnostic services. Its diverse array of supplementary services includes digital X-rays, ultrasounds, electrocardiograms, laboratory analyses, sub-acute care, and patient transportation, which can be provided either in patients' residences or at long-term care facilities. The company also engages in the leasing of real estate properties. As of April 4, 2022, Ensign operated a network of 252 healthcare facilities spread across thirteen U.S. states: Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington, and Wisconsin. The Ensign Group, Inc. was established in 1999 and is headquartered in San Juan Capistrano, California.
- CEO
- Barry R. Port
- Employees
- 46K
- Beta
- 0.69
Included in
Explore
Frequently asked questions
What is the intrinsic value of The Ensign Group, Inc. (ENSG)?
The Ensign Group, Inc. (ENSG) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is ENSG undervalued?
ENSG trades at a price of $176.32 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.